Alumis Inc. Common Stock
(ALMS)
undefined
undefined%
At close: undefined
8.39
-0.47%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases.
The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.
The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Alumis Inc. Common Stock
| Country | United States |
| IPO Date | Feb 22, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Martin Babler Ph.D. |
Contact Details
Address: 280 East Grand Avenue South San Francisco, California United States | |
| Website | https://www.alumis.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US0223071020 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Martin Babler Ph.D. | President, Chief Executive Officer & Chairman |
| John R. Schroer C.F.A. | Chief Financial Officer |
| Sara Klein | Chief Legal Officer & Corporate Secretary |
| Claire Langrish Ph.D. | Senior Vice President & Head of Immunology and Translational Science |
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer |
| Kolbot By Ph.D. | Senior Vice President & Head of Technical Operations |
| Mark Bradley | Chief Development Officer |
| Philip Nunn Ph.D. | Senior Vice President of Pharmacology & Project Team Leader |
| Roy C. Hardiman J.D. | Chief Business Officer |